Nomura retained its Buy rating on Lupin Ltd and raised its target price to Rs 2,780 from Rs 2,675, citing attractive valuations despite expectations of near-term weakness in its US business. The brokerage believes the concerns around declining US sales are largely reflected in the stock's current valuation, making the risk-reward favourable over the next one to two years.
Nomura's revised target price implies an upside of around 40.6% from the closing price of Rs 1,977 on November 16. The brokerage has based its target on 30 times its estimated FY29 earnings per share of Rs 92.70. It said Lupin's valuation multiples are currently towards the lower end of their six-year range, with the stock trading at 11.8 times one-year forward EV/EBITDA and 20.5 times one-year forward price-to-earnings, based on Bloomberg consensus estimates.
Lupin shares touched a high of Rs 1,993, up 2% from the previous close of Rs 1,953.90. The stock opened at Rs 1,960.40 and hit a low of Rs 1,946.60 during the session. It was last trading at Rs 1,968.95, up 0.77%.
The brokerage expects Lupin's US sales to decline in the near term as competition increases for three key products, gJynarque, gMyrbetriq and gSpiriva Handihaler. These products contributed around 40% of the company's US revenue in the September 2026 quarter. However, Nomura expects the erosion to be slower than management's guidance and estimates FY27 US sales at $1.25 billion, above the company's guidance of $1.1 billion to $1.2 billion.
Nomura expects additional competition to affect sales of gJynarque and gMyrbetriq, while pricing pressure could weigh on gSpiriva. It has also factored in lower base business sales in the US, currency movements, slower growth in select markets such as Brazil and higher expenses. Following these changes, the brokerage cut its earnings estimates for FY27, FY28 and FY29 by 14%, 2% and 8%, respectively.
Despite these near-term pressures, the brokerage sees support from Lupin's domestic formulations business, a strong balance sheet and its pipeline of complex generics. It expects India's formulations business to grow 20-30% ahead of the broader market, supported by chronic therapies such as cardiac, diabetes and respiratory treatments. These segments account for 62% of the company's India sales.
Disclaimer: Business Today provides stock market news for informational purposes only and should not be construed as investment advice. Readers are encouraged to consult with a qualified financial advisor before making any investment decisions.